ZA200300406B - Somatostatin analogues. - Google Patents

Somatostatin analogues.

Info

Publication number: ZA200300406B
Authority: ZA; South Africa
Prior art keywords: somatostatin analogues; somatostatin; analogues
Prior art date: 2000-08-01

Application number

ZA200300406A

Other languages

English (en)

Inventor

Rainer Albert

David Bodmer

Ivo Felner

Ian Lewis

Gisbert Weckbecker

Wilfried Bauer

Christian Bruns

Heribert Hellstern

Mark Meisenbach

Bernhard Wietfeld

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-01

Filing date

2003-01-15

Publication date

2004-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9896782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200300406(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-01-15 Application filed by Novartis Ag filed Critical Novartis Ag

2004-04-02 Publication of ZA200300406B publication Critical patent/ZA200300406B/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Virology (AREA)
Oncology (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)

ZA200300406A 2000-08-01 2003-01-15 Somatostatin analogues. ZA200300406B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0018891.2A GB0018891D0 (en)	2000-08-01	2000-08-01	Organic compounds

Publications (1)

Publication Number	Publication Date
ZA200300406B true ZA200300406B (en)	2004-04-02

Family

ID=9896782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200300406A ZA200300406B (en)	2000-08-01	2003-01-15	Somatostatin analogues.

Country Status (36)

Country	Link
US (5)	US7473761B2 (xx)
EP (1)	EP1307486B1 (xx)
JP (1)	JP3829118B2 (xx)
KR (2)	KR20030033008A (xx)
CN (1)	CN1267451C (xx)
AR (1)	AR034132A1 (xx)
AT (1)	ATE393782T1 (xx)
AU (2)	AU2001289778B2 (xx)
BE (1)	BE2012C026I2 (xx)
BR (1)	BRPI0112859B8 (xx)
CA (1)	CA2416293C (xx)
CY (2)	CY1108547T1 (xx)
CZ (1)	CZ302461B6 (xx)
DE (1)	DE60133823T2 (xx)
DK (1)	DK1307486T3 (xx)
EC (1)	ECSP034456A (xx)
ES (1)	ES2305104T3 (xx)
FR (1)	FR12C0041I2 (xx)
GB (1)	GB0018891D0 (xx)
HK (1)	HK1057051A1 (xx)
HU (1)	HU227812B1 (xx)
IL (2)	IL153920A0 (xx)
LU (1)	LU92024I2 (xx)
MX (1)	MXPA03000991A (xx)
MY (1)	MY138074A (xx)
NO (2)	NO331093B1 (xx)
NZ (1)	NZ523836A (xx)
PE (1)	PE20020176A1 (xx)
PL (1)	PL204161B1 (xx)
PT (1)	PT1307486E (xx)
RU (1)	RU2287533C2 (xx)
SI (1)	SI1307486T1 (xx)
SK (1)	SK287798B6 (xx)
TW (1)	TWI282341B (xx)
WO (1)	WO2002010192A2 (xx)
ZA (1)	ZA200300406B (xx)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds
US7189856B2 (en)	2001-12-28	2007-03-13	Gideon Shapiro	Non-peptide somatostatin receptor ligands
BR0317176A (pt)	2002-12-12	2005-10-25	Novartis Ag	Processo para a sìntese de peptìdeos contendo uma subestrutura de 4-hidróxi-prolina
GB0229020D0 (en) *	2002-12-12	2003-01-15	Novartis Ag	Organic compounds
GB0300095D0 (en) *	2003-01-03	2003-02-05	Novartis Ag	Organic compounds
PE20050285A1 (es) *	2003-06-24	2005-06-09	Novartis Ag	Composicion farmaceutica que comprende analogos ciclicos de somatostatina
GB0314695D0 (en) *	2003-06-24	2003-07-30	Novartis Ag	Organic compounds
GB0318682D0 (en) *	2003-08-08	2003-09-10	Novartis Ag	Organic compounds
EP1522311A1 (fr) *	2003-10-10	2005-04-13	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
MY158342A (en) *	2003-11-14	2016-09-30	Novartis Ag	Pharmaceutical composition
GB0412866D0 (en) *	2004-06-09	2004-07-14	Novartis Ag	Organic compounds
GB0428151D0 (en)	2004-12-22	2005-01-26	Novartis Ag	Organic compounds
GB0602639D0 (en)	2006-02-09	2006-03-22	Novartis Ag	Organic compounds
MX2008015666A (es) *	2006-06-08	2009-01-12	Novartis Ag	Combinacion de analogos de somatostatina con un agonista de dopamina o un antagonista del receptor de hormona de crecimiento.
US7697338B2 (en) *	2006-11-16	2010-04-13	Sandisk Corporation	Systems for controlled boosting in non-volatile memory soft programming
WO2008064570A1 (en) *	2006-11-28	2008-06-05	The University Of Hong Kong	The use of granulin-epithelin precursor (gep) antibodies for detection and suppression of hepatocellular carcinoma (hcc)
EP1941902A1 (en) *	2007-01-02	2008-07-09	Novartis AG	Use of Somatostatin analogs in cluster headache
ES2558928T3 (es)	2007-01-31	2016-02-09	Dana-Farber Cancer Institute, Inc.	Péptidos p53 estabilizados y usos de los mismos
KR101525754B1 (ko)	2007-03-28	2015-06-09	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	스티칭된 폴리펩티드
PE20090387A1 (es)	2007-05-24	2009-04-28	Novartis Ag	Formulacion de pasireotida
WO2009009035A1 (en) *	2007-07-06	2009-01-15	Ipsen Pharma S.A.S.	Somatostatin analog and uses thereof
GB0719818D0 (en) *	2007-10-11	2007-11-21	Asterion Ltd	Growth hormone fusion polypeptides
MX2010005936A (es) *	2007-11-28	2010-06-15	Novartis Ag	Uso de analogos de somatostatina en meningioma.
EP2067786A1 (en)	2007-12-07	2009-06-10	ITALFARMACO S.p.A.	Novel non selective analogs of somatostatin
EP2225271B1 (en) *	2007-12-03	2013-07-31	ITALFARMACO S.p.A.	New non-selective somatostatin analogues
US20090325863A1 (en) *	2008-06-13	2009-12-31	Kleinberg David L	Somatostatin analogs and IGF-I inhibition for breast cancer prevention
SI2310042T1 (sl)	2008-07-08	2013-03-29	Novartis Ag	Uporaba pasireotida za zdravljenje endogene hiperinzulinemične hipoglikemije
EP2172189A1 (en)	2008-10-01	2010-04-07	Novartis AG	Pharmaceutical Compositions
EP2213307A1 (en)	2009-02-03	2010-08-04	Novartis AG	Injectable depot formulations
US20100105627A1 (en)	2008-09-17	2010-04-29	Paul Salama	Pharmaceutical compositions and related methods of delivery
UY33236A (es)	2010-02-25	2011-09-30	Novartis Ag	Inhibidores dimericos de las iap
MX355543B (es)	2010-08-13	2018-04-20	Aileron Therapeutics Inc Star	Macrociclos peptidomiméticos.
WO2012074559A2 (en)	2010-12-02	2012-06-07	New York University	Treatment of non-proliferative cystic disease
EP2651917A1 (en)	2010-12-13	2013-10-23	Novartis AG	Dimeric iap inhibitors
UY33794A (es)	2010-12-13	2012-07-31	Novartis Ag	Inhibidores diméricos de las iap
US20130035054A1 (en) *	2011-07-14	2013-02-07	Faceon Mobile	Phone with multi-portal access for display during incoming and outgoing call
US8835123B2 (en)	2011-08-02	2014-09-16	New York University	Methods for detecting progenitor cells and uses thereof
BR112014007310A2 (pt)	2011-09-27	2017-04-04	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
KR20140100937A (ko)	2011-10-18	2014-08-18	에일러론 테라퓨틱스 인코포레이티드	펩티도미메틱 거대고리
MX2014006736A (es)	2011-12-05	2014-08-29	Novartis Ag	Derivados de urea ciclicos como antagonistas de los receptores de androgeno.
BR112014013693B1 (pt)	2011-12-05	2023-01-31	Camurus Ab	Pré-formulação, e, uso de uma pré-formulação
AU2013208720A1 (en)	2012-01-09	2014-07-24	Arrowhead Research Corporation	RNAi agents to treat Beta-Catenin related diseases
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
WO2013123266A1 (en)	2012-02-15	2013-08-22	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
CA2864120A1 (en)	2012-02-15	2013-08-22	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG11201407678YA (en) *	2012-05-25	2014-12-30	Camurus Ab	Somatostatin receptor agonist formulations
TWI704919B (zh) *	2012-05-31	2020-09-21	日商大塚製藥股份有限公司	用於預防及/或治療多囊性腎臟病之藥物
US9604919B2 (en)	2012-11-01	2017-03-28	Aileron Therapeutics, Inc.	Disubstituted amino acids and methods of preparation and use thereof
EP2922578B1 (en)	2012-11-21	2018-12-12	Serene, Llc	Tin-117m comprising somatostatin receptor binding compounds
MX359471B (es)	2013-02-19	2018-09-28	Novartis Ag	Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrogeno.
CA2903176A1 (en)	2013-03-14	2014-09-18	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX355945B (es)	2013-03-14	2018-05-07	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2014147586A1 (en)	2013-03-22	2014-09-25	Novartis Ag	1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
CN103467575B (zh) *	2013-08-22	2016-03-02	深圳翰宇药业股份有限公司	一种帕西瑞肽的制备方法
CN103641894B (zh) *	2013-12-06	2015-10-28	深圳翰宇药业股份有限公司	一种治疗库欣病的多肽药物的制备方法
WO2015092634A1 (en)	2013-12-16	2015-06-25	Novartis Ag	1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2015092690A1 (en)	2013-12-19	2015-06-25	Novartis Ag	Drug delivery systems
JO3517B1 (ar)	2014-01-17	2020-07-05	Novartis Ag	ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699354T3 (es)	2014-01-17	2019-02-08	Novartis Ag	Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
CN105899491B (zh)	2014-01-17	2019-04-02	诺华股份有限公司	用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
MY187246A (en)	2014-03-14	2021-09-14	Novartis Ag	Antibody molecules to lag-3 and uses thereof
WO2015181624A2 (en)	2014-05-28	2015-12-03	Idenix Pharmaceuticals, Inc	Nucleoside derivatives for the treatment of cancer
CN112245565A (zh)	2014-09-24	2021-01-22	艾瑞朗医疗公司	拟肽大环化合物及其用途
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40035A (fr)	2014-10-14	2016-04-21	Dana Farber Cancer Inst Inc	Molécules d'anticorps de pd-l1 et leurs utilisations
US10508108B2 (en)	2014-12-05	2019-12-17	Merck Sharp & Dohme Corp.	Tricyclic compounds as inhibitors of mutant IDH enzymes
WO2016089797A1 (en)	2014-12-05	2016-06-09	Merck Sharp & Dohme Corp.	Novel tricyclic compounds as inhibitors of mutant idh enzymes
EP3226690B1 (en)	2014-12-05	2020-05-20	Merck Sharp & Dohme Corp.	Novel tricyclic compounds as inhibitors of mutant idh enzymes
CA2970519A1 (en)	2014-12-10	2016-06-16	Chiasma Inc.	Oral octreotide administered in combination with other therapeutic agents
US20210317161A1 (en) *	2014-12-19	2021-10-14	Auro Peptides Ltd	A process for the preparation of pasireotide
EP3233918A1 (en)	2014-12-19	2017-10-25	Novartis AG	Combination therapies
US10238709B2 (en)	2015-02-03	2019-03-26	Chiasma, Inc.	Method of treating diseases
PE20171448A1 (es)	2015-03-10	2017-10-02	Aduro Biotech Inc	Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
BR112017019738A2 (pt)	2015-03-20	2018-05-29	Aileron Therapeutics Inc	macrociclos peptidomiméticos e usos dos mesmos
WO2016162127A1 (en) *	2015-04-08	2016-10-13	Polyphor Ag	Backbone-cyclized peptidomimetics
CN108368147A (zh)	2015-05-27	2018-08-03	南方研究院	用于治疗癌症的核苷酸
CN107922388B (zh)	2015-06-19	2020-12-29	诺华股份有限公司	用于抑制shp2活性的化合物和组合物
WO2016203405A1 (en)	2015-06-19	2016-12-22	Novartis Ag	Compounds and compositions for inhibiting the activity of shp2
ES2741746T3 (es)	2015-06-19	2020-02-12	Novartis Ag	Compuestos y composiciones para inhibir la actividad de SHP2
US10556924B2 (en)	2015-06-22	2020-02-11	Biophore India Pharmaceuticals Pvt. Ltd.	Process for the preparation of pasireotide
GB201511790D0 (en)	2015-07-06	2015-08-19	Iomet Pharma Ltd	Pharmaceutical compound
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3328418A1 (en)	2015-07-29	2018-06-06	Novartis AG	Combination therapies comprising antibody molecules to pd-1
MA42608A (fr)	2015-08-13	2018-06-20	Merck Sharp & Dohme	Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
US11453697B1 (en)	2015-08-13	2022-09-27	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
HRP20220436T1 (hr)	2015-11-03	2022-05-27	Janssen Biotech, Inc.	Protutijela koja se specifično vežu na pd-1 i njihove uporabe
US10538497B2 (en)	2015-12-15	2020-01-21	Merck Sharp & Dohme Corp.	Compounds as indoleamine 2,3-dioxygenase inhibitors
WO2017106656A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
CA3023032A1 (en)	2016-05-04	2017-11-09	Genoscience Pharma	Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
AU2017283769B2 (en)	2016-06-14	2019-08-15	Novartis Ag	Compounds and compositions for inhibiting the activity of SHP2
US11098077B2 (en)	2016-07-05	2021-08-24	Chinook Therapeutics, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
MA46452B1 (fr)	2016-10-04	2021-10-29	Merck Sharp & Dohme	Composés de benzo[b]thiophéne en tant qu'agonistes de sting
EP3541825A1 (en)	2016-11-21	2019-09-25	Idenix Pharmaceuticals LLC.	Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
EP3573717B1 (en)	2017-01-27	2021-07-28	Janssen Biotech, Inc.	Cyclic dinucleotides as sting agonists
WO2018138685A2 (en)	2017-01-27	2018-08-02	Janssen Biotech, Inc.	Cyclic dinucleotides as sting agonists
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en)	2017-05-12	2022-10-11	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
US20200172628A1 (en)	2017-06-22	2020-06-04	Novartis Ag	Antibody molecules to cd73 and uses thereof
JP2020529421A (ja)	2017-08-04	2020-10-08	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
WO2019027858A1 (en)	2017-08-04	2019-02-07	Merck Sharp & Dohme Corp.	BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
WO2019051469A1 (en)	2017-09-11	2019-03-14	Krouzon Pharmaceuticals, Inc.	SHP2 OCTAHYDROCYCLOPENTA [C] PYRROLE ALLOSTERIC INHIBITORS
WO2019067332A1 (en)	2017-09-27	2019-04-04	Merck Sharp & Dohme Corp.	COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
US11180497B2 (en) *	2017-10-18	2021-11-23	Angex Pharmaceutical, Inc.	Cyclic compounds as immunomodulating agents
WO2019089412A1 (en)	2017-11-01	2019-05-09	Merck Sharp & Dohme Corp.	Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3709986B1 (en)	2017-11-14	2023-11-01	Merck Sharp & Dohme LLC	Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
AU2018368332B2 (en)	2017-11-14	2022-05-12	Merck Sharp & Dohme Llc	Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CN111712509A (zh)	2017-12-15	2020-09-25	詹森生物科技公司	作为sting激动剂的环状二核苷酸
US11685761B2 (en)	2017-12-20	2023-06-27	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
US11702430B2 (en)	2018-04-03	2023-07-18	Merck Sharp & Dohme Llc	Aza-benzothiophene compounds as STING agonists
TWI793294B (zh)	2018-04-03	2023-02-21	美商默沙東有限責任公司	Sting促效劑化合物
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019231870A1 (en)	2018-05-31	2019-12-05	Merck Sharp & Dohme Corp.	Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
US10596276B2 (en)	2018-07-25	2020-03-24	Advanced Accelerator Applications (Italy) S.R.L.	Stable, concentrated radionuclide complex solutions
US10596278B2 (en)	2018-07-25	2020-03-24	Advanced Accelerator Applications (Italy) S.R.L.	Stable, concentrated radionuclide complex solutions
AU2019344899A1 (en)	2018-09-18	2021-04-15	Nikang Therapeutics, Inc.	Fused tricyclic ring derivatives as Src homology-2 phosphatase inhibitors
JP2022502496A (ja)	2018-09-25	2022-01-11	ブラックダイアモンドセラピューティクス，インコーポレイティド	チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
JP2022502495A (ja)	2018-09-25	2022-01-11	ブラックダイアモンドセラピューティクス，インコーポレイティド	チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
AU2019350592B2 (en)	2018-09-29	2024-09-26	Novartis Ag	Process of manufacture of a compound for inhibiting the activity of SHP2
WO2020092183A1 (en)	2018-11-01	2020-05-07	Merck Sharp & Dohme Corp.	Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
US12065438B2 (en)	2018-11-06	2024-08-20	Merck Sharp & Dohme Llc	Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
US20230008022A1 (en)	2018-11-28	2023-01-12	Merck Sharp & Dohme Corp.	Novel substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3946324A4 (en)	2019-04-04	2022-11-30	Merck Sharp & Dohme LLC	HISTONE DEACETYLASE-3 INHIBITORS USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATIVE DISEASES AND DIABETES
WO2020260547A1 (en)	2019-06-27	2020-12-30	Rigontec Gmbh	Design method for optimized rig-i ligands
TW202120500A (zh)	2019-08-02	2021-06-01	美商梅爾莎納醫療公司	干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途
KR20220047810A (ko)	2019-08-15	2022-04-19	블랙 다이아몬드 테라퓨틱스, 인코포레이티드	알키닐 퀴나졸린 화합물
WO2021053559A1 (en)	2019-09-18	2021-03-25	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN112724127B (zh)	2019-10-28	2023-02-17	中国科学院上海药物研究所	五元杂环氧代羧酸类化合物及其医药用途
EP4069683A1 (en)	2019-12-06	2022-10-12	Mersana Therapeutics, Inc.	Dimeric compounds as sting agonists
WO2021195206A1 (en)	2020-03-24	2021-09-30	Black Diamond Therapeutics, Inc.	Polymorphic forms and related uses
CN115836054A (zh)	2020-05-06	2023-03-21	默沙东有限责任公司	Il4i1抑制剂和使用方法
CA3202355A1 (en)	2020-12-22	2022-06-30	Jiping Fu	Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods
MX2023008296A (es)	2021-01-13	2023-09-29	Monte Rosa Therapeutics Inc	Compuestos de isoindolinona.
WO2022170052A1 (en)	2021-02-05	2022-08-11	Black Diamond Therapeutics, Inc.	Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
EP4323350A1 (en)	2021-04-14	2024-02-21	Monte Rosa Therapeutics AG	Isoindolinone compounds
WO2022219412A1 (en)	2021-04-14	2022-10-20	Monte Rosa Therapeutics Ag	Isoindolinone amide compounds useful to treat diseases associated with gspt1
WO2022227015A1 (en)	2021-04-30	2022-11-03	Merck Sharp & Dohme Corp.	Il4i1 inhibitors and methods of use
EP4370522A1 (en)	2021-07-14	2024-05-22	Nikang Therapeutics, Inc.	Alkylidene derivatives as kras inhibitors
TW202346292A (zh)	2022-03-28	2023-12-01	美商尼坎醫療公司	作為週期蛋白依賴性激酶２抑制劑的磺醯胺基衍生物
WO2023240024A1 (en)	2022-06-08	2023-12-14	Nikang Therapeutics, Inc.	Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2024047112A1 (en) *	2022-08-30	2024-03-07	Somtheranostics Sarl	Halogenated somatostatin analogs with multiple somatostatin receptor subtype selectivity
WO2024102849A1 (en)	2022-11-11	2024-05-16	Nikang Therapeutics, Inc.	Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2024206357A1 (en)	2023-03-29	2024-10-03	Merck Sharp & Dohme Llc	Il4i1 inhibitors and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3863008A (en)	1973-06-11	1975-01-28	American Home Prod	Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en)	1979-10-31	1984-10-19	Merck & Co Inc	Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en)	1980-07-09	1981-10-06	E. R. Squibb & Sons, Inc.	Lyophilized hydrocolloio foam
US4612386A (en) *	1980-09-16	1986-09-16	The Dow Chemical Company	Process for making esters
US4505897A (en)	1983-04-18	1985-03-19	The Administrators Of The Tulane Educational Fund	Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en)	1985-06-17	1986-09-16	Merck & Co., Inc.	Cyclic hexapeptide somatostatin analogs
CA2012115C (en)	1989-03-15	2001-07-03	Biomeasure, Inc.	Iodinated somatostatins
CA2053250A1 (en)	1989-04-26	1990-10-27	David H. Coy	Linear somatostatin analogs
US5716596A (en)	1992-06-23	1998-02-10	Diatide, Inc.	Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en)	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
AU701083B2 (en)	1993-06-23	1999-01-21	Cis Bio International	Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
SG75092A1 (en)	1993-08-09	2000-09-19	Biomeasure Inc	Therapeutic peptide derivatives
US5770687A (en)	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
MY147327A (en) *	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
IT1277391B1 (it)	1995-07-28	1997-11-10	Romano Deghenghi	Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
AU2764797A (en)	1996-05-14	1997-12-05	Novo Nordisk A/S	Somatostatin agonists and antagonists
US6355613B1 (en)	1996-07-31	2002-03-12	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
CA2246791A1 (en)	1998-09-01	2000-03-01	Alison Buchan	Treatment of endothelium with somatostatin analogues
GB0018891D0 (en) *	2000-08-01	2000-09-20	Novartis Ag	Organic compounds

2000
- 2000-08-01 GB GBGB0018891.2A patent/GB0018891D0/en not_active Ceased
2001
- 2001-07-26 PE PE2001000760A patent/PE20020176A1/es active IP Right Grant
- 2001-07-26 TW TW090118314A patent/TWI282341B/zh active
- 2001-07-30 CN CNB018136869A patent/CN1267451C/zh not_active Expired - Lifetime
- 2001-07-30 WO PCT/EP2001/008824 patent/WO2002010192A2/en active IP Right Grant
- 2001-07-30 RU RU2003105817/04A patent/RU2287533C2/ru active Protection Beyond IP Right Term
- 2001-07-30 AU AU2001289778A patent/AU2001289778B2/en active Active
- 2001-07-30 CA CA2416293A patent/CA2416293C/en not_active Expired - Lifetime
- 2001-07-30 NZ NZ523836A patent/NZ523836A/en not_active IP Right Cessation
- 2001-07-30 MX MXPA03000991A patent/MXPA03000991A/es active IP Right Grant
- 2001-07-30 MY MYPI20013578A patent/MY138074A/en unknown
- 2001-07-30 JP JP2002515921A patent/JP3829118B2/ja not_active Expired - Lifetime
- 2001-07-30 SI SI200130836T patent/SI1307486T1/sl unknown
- 2001-07-30 IL IL15392001A patent/IL153920A0/xx unknown
- 2001-07-30 US US10/343,288 patent/US7473761B2/en active Active
- 2001-07-30 SK SK121-2003A patent/SK287798B6/sk not_active IP Right Cessation
- 2001-07-30 PT PT01969555T patent/PT1307486E/pt unknown
- 2001-07-30 AU AU8977801A patent/AU8977801A/xx active Pending
- 2001-07-30 BR BRPI0112859A patent/BRPI0112859B8/pt not_active IP Right Cessation
- 2001-07-30 PL PL358718A patent/PL204161B1/pl unknown
- 2001-07-30 KR KR10-2003-7001435A patent/KR20030033008A/ko not_active Application Discontinuation
- 2001-07-30 EP EP01969555A patent/EP1307486B1/en not_active Expired - Lifetime
- 2001-07-30 AR ARP010103642A patent/AR034132A1/es active IP Right Grant
- 2001-07-30 DE DE60133823T patent/DE60133823T2/de not_active Expired - Lifetime
- 2001-07-30 DK DK01969555T patent/DK1307486T3/da active
- 2001-07-30 AT AT01969555T patent/ATE393782T1/de active
- 2001-07-30 HU HU0300684A patent/HU227812B1/hu active Protection Beyond IP Right Term
- 2001-07-30 CZ CZ20030288A patent/CZ302461B6/cs unknown
- 2001-07-30 ES ES01969555T patent/ES2305104T3/es not_active Expired - Lifetime
- 2001-07-30 KR KR1020067005526A patent/KR100799394B1/ko active IP Right Grant
2003
- 2003-01-13 IL IL153920A patent/IL153920A/en active Protection Beyond IP Right Term
- 2003-01-15 ZA ZA200300406A patent/ZA200300406B/xx unknown
- 2003-01-29 EC EC2003004456A patent/ECSP034456A/es unknown
- 2003-01-30 NO NO20030484A patent/NO331093B1/no not_active IP Right Cessation
- 2003-11-07 HK HK03108087A patent/HK1057051A1/xx not_active IP Right Cessation
2008
- 2008-07-29 CY CY20081100789T patent/CY1108547T1/el unknown
- 2008-11-05 US US12/265,135 patent/US7939625B2/en not_active Expired - Fee Related
2011
- 2011-03-16 US US13/048,935 patent/US9035021B2/en not_active Expired - Lifetime
- 2011-03-16 US US13/048,932 patent/US8822637B2/en not_active Expired - Lifetime
2012
- 2012-06-20 LU LU92024C patent/LU92024I2/fr unknown
- 2012-06-21 BE BE2012C026C patent/BE2012C026I2/fr unknown
- 2012-06-26 FR FR12C0041C patent/FR12C0041I2/fr active Active
- 2012-06-29 CY CY2012018C patent/CY2012018I1/el unknown
- 2012-06-29 NO NO2012012C patent/NO2012012I2/no not_active IP Right Cessation
2015
- 2015-04-08 US US14/681,226 patent/US20150218223A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SK1212003A3 (en)	2003-08-05
IL153920A (en)	2010-12-30
EP1307486B1 (en)	2008-04-30
HUP0300684A2 (hu)	2003-09-29
MY138074A (en)	2009-04-30
CY1108547T1 (el)	2014-04-09
AU8977801A (en)	2002-02-13
US9035021B2 (en)	2015-05-19
US20090069225A1 (en)	2009-03-12
RU2287533C2 (ru)	2006-11-20
JP3829118B2 (ja)	2006-10-04
CZ302461B6 (cs)	2011-06-01
KR20060035809A (ko)	2006-04-26
AR034132A1 (es)	2004-02-04
GB0018891D0 (en)	2000-09-20
KR20030033008A (ko)	2003-04-26
NO2012012I2 (no)	2012-07-30
KR100799394B1 (ko)	2008-01-30
US20110166320A1 (en)	2011-07-07
US20150218223A1 (en)	2015-08-06
ATE393782T1 (de)	2008-05-15
US8822637B2 (en)	2014-09-02
US20050014686A1 (en)	2005-01-20
WO2002010192A3 (en)	2002-09-19
US7939625B2 (en)	2011-05-10
IL153920A0 (en)	2003-07-31
NZ523836A (en)	2004-08-27
FR12C0041I2 (fr)	2013-01-11
CY2012018I2 (el)	2015-10-07
WO2002010192A9 (en)	2002-10-17
HU227812B1 (hu)	2012-03-28
PE20020176A1 (es)	2002-03-26
HUP0300684A3 (en)	2004-08-30
DK1307486T3 (da)	2008-08-25
JP2004505095A (ja)	2004-02-19
NO20030484L (no)	2003-03-19
DE60133823D1 (de)	2008-06-12
CY2012018I1 (el)	2015-10-07
PT1307486E (pt)	2008-07-31
WO2002010192A2 (en)	2002-02-07
MXPA03000991A (es)	2003-06-09
ECSP034456A (es)	2003-03-10
PL204161B1 (pl)	2009-12-31
US7473761B2 (en)	2009-01-06
NO331093B1 (no)	2011-10-03
CZ2003288A3 (cs)	2003-05-14
NO2012012I1 (no)	2012-06-29
FR12C0041I1 (xx)	2012-07-27
LU92024I2 (fr)	2012-08-20
BR0112859A (pt)	2003-07-01
BRPI0112859B8 (pt)	2021-05-25
ES2305104T3 (es)	2008-11-01
NO20030484D0 (no)	2003-01-30
SK287798B6 (sk)	2011-10-04
HK1057051A1 (en)	2004-03-12
CN1267451C (zh)	2006-08-02
PL358718A1 (en)	2004-08-09
CA2416293A1 (en)	2002-02-07
SI1307486T1 (sl)	2008-08-31
BRPI0112859B1 (pt)	2016-03-01
CN1446229A (zh)	2003-10-01
TWI282341B (en)	2007-06-11
AU2001289778B2 (en)	2005-02-03
EP1307486A2 (en)	2003-05-07
DE60133823T2 (de)	2009-05-20
BE2012C026I2 (xx)	2020-12-15
CA2416293C (en)	2011-05-10
US20110172157A1 (en)	2011-07-14

Publication	Publication Date	Title
ZA200300406B (en)	2004-04-02	Somatostatin analogues.
MXPA03002410A (es)	2003-06-19	4-amino-quinazolinas.
GB0128526D0 (en)	2002-01-23	Nucleotide analogues
EG23262A (en)	2004-10-31	Delta -pyrrolines.
HK1055426A1 (en)	2004-01-09	Indoloquinazolinones.
MXPA03001591A (es)	2003-09-10	Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03009048A (es)	2004-02-12	Agonistas de la somatostatina.
ZA200203390B (en)	2004-02-11	Vitamin D analogues.
MXPA03001877A (es)	2003-06-24	2-guanidin-4-arilquinazolinas.
MXPA03002668A (es)	2003-08-20	Guanidinas de sulfonilo.
MXPA03001991A (es)	2003-06-24	Novedosas arilalcano-sulfonamidas.
MXPA03005714A (es)	2003-10-06	Sulfamidotienopirimidinas.
MXPA03002411A (es)	2003-06-19	4-amino-quinazolinas.
ZA200106875B (en)	2001-09-05	Trace elements.
MXPA03005494A (es)	2003-10-06	Benzoilpiridazinas.
HK1061560A1 (en)	2004-09-24	Triazolo-epothilones.
GB0022877D0 (en)	2000-11-01	Analogues
HK1051179A1 (en)	2003-07-25	Prostaglandin e analogues.
GB0002612D0 (en)	2000-03-29	C.m.e
HK1051197A1 (en)	2003-07-25	Novel vitamin d analogues.
ZA200302241B (en)	2004-03-23	Triazolo-epothilones.
TJ414B (en)	2005-07-14	Thermoresistor.
GB0024269D0 (en)	2000-11-15	D.p.s.
ZA200103473B (en)	2002-09-26	Headware.
GB0027716D0 (en)	2000-12-27	P:c:d.